Mitoxantrone—A Useful Palliative Therapy in Advanced Breast Cancer

Jf, Robertson; Mr, Williams; Jh, Todd; Rw, Blamey

doi:10.1097/00000421-198910000-00006

Cited by 11 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mitoxantrone is a synthetic anthracenedione that has demonstrated activity against metastatic breast cancer in previous studies [35,36]. In addition to our previous positive experience with mitoxantrone in the treatment of malignant pleural effusions, this was the main reason for us to choose this agent, despite the fact that it is more expensive than others.…”

Section: Discussionmentioning

confidence: 99%

Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer

2004

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer

2004

View full text Add to dashboard Cite

show abstract

“…In most reports, a statistically significant difference in favor of MIX was shown for toxicity parameters such as alopecia, mucositis/stomatitis, nausea and vomiting [24,[30][31][32]. In contrast, Adriamycin causes severe alopecia which occurs abruptly and has severe psychological effects; mucositis and stomatitis can become a grave problem, causing cessation of therapy.…”

Section: Discussionmentioning

confidence: 99%

Mitoxantrone as Second-Line Single Agent in Metastatic Breast Cancer

Stein¹,

Borovik²,

Robinson³

1991

Oncology

View full text Add to dashboard Cite

Mitoxantrone (MIX), a member of the anthraquinone chemical class, was found to be a potential anticancer agent. It has a similar spectrum of activity as Adriamycin in experimental and human tumors. Thirty-five female patients with metastatic breast cancer, refractory to previous chemotherapy, were treated between 1986 and 1987 with MIX (14 mg/m² i.v. every 3 weeks); patients with diffuse bone metastases or heavily pretreated patients received 10–12 mg/m² MIX. All patients were evaluable for response and toxicity. Two patients achieved complete response and 4 partial response, giving an overall response rate of 17%. Median time of response was 5.5 months. The drug was well tolerated. Objective response was obtained mostly in patients with a performance status (Karnofsky scale) of more than 70%, and in those who received more than 12 mg/m² MIX per course. One patient developed cardiomyopathy, another an acute myocardial infarction, and 3 patients had pathological changes on echocardiography or multigated nuclear angiography. Hematological and gastrointestinal toxicity was tolerable. We found MIX to be a potentially effective second-line treatment with mild toxicity in patients with metastatic breast cancer.

show abstract

“…We chose to study xenografts derived from human breast and prostate cancers because these types of tumor have moderate clinical sensitivity to mitoxantrone (20,21). The PC-3 prostate tumor is well characterized, and we have already studied doxorubicin penetration in PC-3 xenografts (15).…”

Section: Introductionmentioning

confidence: 99%

The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone

Trédan

Garbens

Lalani³

et al. 2009

Cancer Research

View full text Add to dashboard Cite

Hypoxic tumor cells are likely to be resistant to conventional chemotherapy, in large part because many anticancer drugs are unable to penetrate into poorly oxygenated tumor tissue. Here, we used quantitative immunofluorescence to study the distribution of mitoxantrone and AQ4N in tumor tissue. AQ4N is a prodrug activated under hypoxic conditions to AQ4, which is structurally similar to mitoxantrone and inhibits topoisomerase II. We characterized the penetration of mitoxantrone and AQ4N/AQ4 through multilayered cell cultures (MCC) and in relation to blood vessels and hypoxic regions in human tumor xenografts. We also studied tumor growth delay after treatment with each agent alone and with the combination. In both MCC and xenografts, mitoxantrone is taken up by proximal cells and penetrates slowly to distant regions. In contrast, AQ4N rapidly penetrates MCC and tumor tissue in vivo, and AQ4N (or its reduced form AQ4) is detected at high concentration within hypoxic regions. The targeting of mitoxantrone to oxygenated regions and AQ4N/AQ4 to hypoxic tumor regions results in effective drug exposure over the entire tumor after combined treatment and increases tumor growth delay compared with either drug alone. The combination of a clinically used anticancer drug with limited tissue penetration and a structurally related drug activated in regions of tumor hypoxia is an effective strategy to overcome chemoresistance due to the tumor microenvironment. This study supports clinical evaluation of AQ4N in combination with conventional anticancer agents, such as mitoxantrone.

show abstract

Mitoxantrone—A Useful Palliative Therapy in Advanced Breast Cancer

Cited by 11 publications

References 0 publications

Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer

Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer

Mitoxantrone as Second-Line Single Agent in Metastatic Breast Cancer

The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone

Contact Info

Product

Resources

About